Melatonin as a potential adjunct therapy for central nervous system lupus: evidence from the MRL/lpr mouse model

Acknowledgements

This work was supported by the National Institutes of Health (Grant No. 1R01DK111222, to J.J.A.) and the Dr Arthur M. Morris endowment (to R.J.Q.).

Author contributions

Jaivarshaan Rajkumar (Data curation, Investigation, Methodology), Alexandra Spath (Data curation, Investigation, Methodology, Validation), Hyndevi Dokuri (Data curation, Methodology), Alexander Jacob (Methodology, Supervision, Validation, Writing—original draft), Richard J. Quigg (Conceptualization, Data curation, Resources, Writing—review & editing), and Jessy Alexander (Conceptualization, Methodology, Project administration, Supervision, Validation, Writing—original draft, Writing—review & editing)

Supplementary data

Supplementary data are available at PCMEDI online.

Conflict of interest

None declared. As an Editorial Board Member of Precision Clinical Medicine, the corresponding author J.J.A. was blinded from reviewing and making decisions on this manuscript.

Ethics statetment

All mice procedures and work described in this study were approved by the Institutional Animal Care and Use Committee. The protocol complies with the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals, and the ethical principles established by the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8523, revised 2011).

References

[1] Tsoi A, Gomez A, Bostrom C et al. Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature. Rheumatol Int 2024;44:76578. https://doi.org/10.1007/s00296-024-05548-x.

[2] Palagini L, Tani C, Mauri M et al. Sleep disorders and systemic lupus erythematosus. Lupus 2014;23:115-23. https://doi.org/10.1177/0961203313518623.

[3] Robeva R, Tanev D, Kirilov G et al. Decreased daily melatonin levels in women with systemic lupus erythematosus-a short report. Balkan Med J 2013;30:273-6. https://doi.org/10.5152/balkan medj.2013.8064.

[4] Rama Rao KV, Verkman AS, Curtis KM et al. Aquaporin-4 deletion in mice reduces encephalopathy and brain edema in experimental acute liver failure. Neurobiol Dis 2014;63:222-8. https://doi.org/10.1016/j.nbd.2013.11.018.

[5] Pramanik R, Jorgensen TN, Xin H et al. Interleukin-6 induces expression of Ifi202, an interferon-inducible candidate gene for lupus susceptibility. J Biol Chem 2004;279:16121-7. https://doi.org/10.1074/jbc.M313140200.

[6] Laassila S, Aboulem G, Chtaou N et al. Intracranial hypertension with reversible cerebral edema: Atypical presentation of neuropsychiatric systemic lupus erythematosus. Radiology Case Reports 2022;17:1416-20. https://doi.org/10.1016/j.radcr.2022.02.018.

[7] Zouari R, Saeid MZ, Marzouk M et al. Diffuse cerebral edema with leukoencephalopathy revealing systemic lupus erythematosus: A case report and review of literature. Lupus 2023;32:1561-71. https://doi.org/10.1177/09612033231207723.

[8] Alexander JJ, Bao L, Jacob A et al. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 2003;1639:169-76. https://doi.org/10.1016/j.bbadis.2003.09.005.

[9] Lechner O, Dietrich H,Oliveira dos Santos A et al. Altered circadian rhythms of the stress hormone and melatonin response in lupus-prone MRL/MP-fas(Ipr) mice. J Autoimmun 2000;14:325-33. https://doi.org/10.1006/jaut.2000.0375.

[10] Jimenez-Caliani AJ, Jimenez-Jorge S, Molinero P et al. Sexdependent effect of melatonin on systemic erythematosus lupus developed in Mrl/Mpj-Faslpr mice: it ameliorates the disease course in females, whereas it exacerbates it in males. Endocrinology 2006;147:1717-24. https://doi.org/10.1210/en. 200 5-0648.